drugset / Trial / NCT05222516

Immunomodulation by OM-85 (Broncho-Vaxom) in Early AD

NCT05222516

Phase 2 Terminated 63 enrolled OM Pharma SA
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Clinical data suggest that treatment with OM-85, by inducing an early contact with bacterial extracts, could modulate the immunity of children with Atopic Dermatitis, and thus play an active role in the treatment of Atopic Dermatitis. The present trial will investigate the influence of administration of OM-85 in the paediatric population younger than 24 months with moderate atopic dermatitis. The efficacy and safety of OM-85 will be evaluated in children aged 3 to 24 months old with moderate Atopic Dermatitis who may benefit from treatment with OM-85. The placebo treatment period will serve as a reference and has been added to establish efficacy and safety.

Timeline

Start
2021-12-20
Primary completion
2023-07-13
Completion
2023-07-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Broncho-Vaxom Other / unclassified 3.5 mg Oral

Indications